Georg Ertl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Georg Ertl has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
- Christiane E. Angermann
Comprehensive Heart Failure Centre, University and University Hospital of Würzburg, Würzburg, Germany
8 shared publications - Stefan Störk
Department of Clinical Research and Epidemiology, Comprehensive Heart Failure Center, University Hospital Wurzburg , Wurzburg
6 shared publications - Stefan Frantz
Medizinische Klinik und Poliklinik I, Universitätsklinikum Würzburg, Würzburg, Deutschland
4 shared publications - Caroline Morbach
Department of Clinical Research and Epidemiology, Comprehensive Heart Failure Center and Department of Medicine I, University Hospital Würzburg, Würzburg, Germany
3 shared publications - Aldo Pietro Maggioni
Centro Studi ANMCO—Heart Care Foundation, 50121 Florence, Italy
2 shared publications - Christoph Maack
University Hospital of Würzburg
2 shared publications
Latest Publications
- Open Access
- 19 October 2026
- Published by Springer Nature in Current Heart Failure Reports
- Vol. 23 (1) , 49
Personalized Remote Patient Management in Heart Failure
Purpose of Review: Implanted pulmonary artery pressure (PAP) monitoring provides an early window on imminent worsening heart failure (HF). Randomized trials demonstrated that PAP-guided management significantly reduces HF hospitalizations, but substantial residual risk persists despite recent major advances in HF pharmacotherapy. We review lessons from PAP-guided remote patient management and examine how artificial intelligence (AI) could support more individualized eligibility assessment and multimodal longitudinal surveillance within a patient-centered adaptive care cycle to further improve clinical outcomes. Recent Findings: HF is increasingly recognized as a systemic disease characterized, across HF phenotypes, by multiple cardiac and non-cardiac comorbidities. CHAMPION, GUIDE-HF, and MONITOR-HF did not systematically incorporate comorbidity-related risk into patient selection, while PAP-guided treatment focused predominantly on diuretic adjustment, and monitoring strategies were not adapted to individual disease trajectories. Summary: AI could help integrate multidimensional phenotyping to estimate individual risk and expected benefit pre-implant, use comprehensive longitudinal monitoring data to support personalized, actionable clinical decision-making, and enable dynamic adaptation of monitoring intensity tailored to the disease trajectory. This may improve clinical outcomes, reduce healthcare professional workload, enhance patient experience and treatment adherence, and increase cost-effectiveness.
- 19 October 2026
- Published by Springer Nature in Current Heart Failure Reports
- Vol. 23 (1) , 49
Open AccessPersonalized Remote Patient Management in Heart Failure
Purpose of Review: Implanted pulmonary artery pressure (PAP) monitoring provides an early window on imminent worsening heart failure (HF). Randomized trials demonstrated that PAP-guided management significantly reduces HF hospitalizations, but substantial residual risk persists despite recent major advances in HF pharmacotherapy. We review lessons from PAP-guided remote patient management and examine how artificial intelligence (AI) could support more individualized eligibility assessment and multimodal longitudinal surveillance within a patient-centered adaptive care cycle to further improve clinical outcomes. Recent Findings: HF is increasingly recognized as a systemic disease characterized, across HF phenotypes, by multiple cardiac and non-cardiac comorbidities. CHAMPION, GUIDE-HF, and MONITOR-HF did not systematically incorporate comorbidity-related risk into patient selection, while PAP-guided treatment focused predominantly on diuretic adjustment, and monitoring strategies were not adapted to individual disease trajectories. Summary: AI could help integrate multidimensional phenotyping to estimate individual risk and expected benefit pre-implant, use comprehensive longitudinal monitoring data to support personalized, actionable clinical decision-making, and enable dynamic adaptation of monitoring intensity tailored to the disease trajectory. This may improve clinical outcomes, reduce healthcare professional workload, enhance patient experience and treatment adherence, and increase cost-effectiveness.
- 1 October 2026
- Published by Wolters Kluwer Health in Circulation: Population Health and Outcomes
- Vol. 19 (10)
Effect Modification of Remote Patient Management by Sex and Marital Status Among Patients With Heart Failure in Germany: Findings From the Extended Interdisciplinary Network Heart Failure Trial
BACKGROUND: Previous randomized trials of different remote patient management (RPM) strategies have yielded heterogeneous results in heart failure (HF) populations. It remains unclear whether the effects of RPM are modulated by patient sex and marital status. METHODS: We conducted a secondary analysis of the multicenter, randomized E-INH study (Extended Interdisciplinary Network Heart Failure), which enrolled patients hospitalized with acute systolic HF and a left ventricular ejection fraction ≤40% between 2004 and 2007. Participants were assigned in a 1:1 ratio to receive a telephone-based, nurse-coordinated multidisciplinary RPM strategy (HeartNetCare-HF) plus usual care or usual care alone for 18 months, followed by 42 months of intervention-free follow-up. Patients with available marital status information were included in the present analysis. Flexible parametric Royston-Parmar survival models were used to assess interactions between RPM, sex, and marital status for all-cause death, HF hospitalization, and the composite end point at 18 and 60 months. RESULTS: Of the 1022 randomized participants, 1008 provided information on marital status (mean age, 68±13 years; 28% were women, and 63% were married). Sex and marital status modified the effect of RPM on all-cause death, with a significant 3-way interaction at 18 ( P =0.015) and 60 ( P =0.004) months. At 60 months, all-cause mortality ranged from 28% among married women receiving RPM to almost 60% among unmarried men receiving usual care. The greatest impact of RPM versus usual care on all-cause death was observed among married women: adjusted hazard ratios were 0.32 (95% CI, 0.10–0.98) and 0.44 (0.22–0.88) at 18 and 60 months, respectively. CONCLUSIONS: These findings indicate that the benefits from the RPM strategy HeartNetCare-HF in patients discharged after hospitalization for acute systolic HF were modulated by sex and marital status, both individually and in combination. Future studies are needed to evaluate whether tailoring RPM interventions according to patient sex and marital status optimizes outcomes in patients with HF.
- 1 October 2026
- Published by Wolters Kluwer Health in Circulation: Population Health and Outcomes
- Vol. 19 (10)
Effect Modification of Remote Patient Management by Sex and Marital Status Among Patients With Heart Failure in Germany: Findings From the Extended Interdisciplinary Network Heart Failure Trial
BACKGROUND: Previous randomized trials of different remote patient management (RPM) strategies have yielded heterogeneous results in heart failure (HF) populations. It remains unclear whether the effects of RPM are modulated by patient sex and marital status. METHODS: We conducted a secondary analysis of the multicenter, randomized E-INH study (Extended Interdisciplinary Network Heart Failure), which enrolled patients hospitalized with acute systolic HF and a left ventricular ejection fraction ≤40% between 2004 and 2007. Participants were assigned in a 1:1 ratio to receive a telephone-based, nurse-coordinated multidisciplinary RPM strategy (HeartNetCare-HF) plus usual care or usual care alone for 18 months, followed by 42 months of intervention-free follow-up. Patients with available marital status information were included in the present analysis. Flexible parametric Royston-Parmar survival models were used to assess interactions between RPM, sex, and marital status for all-cause death, HF hospitalization, and the composite end point at 18 and 60 months. RESULTS: Of the 1022 randomized participants, 1008 provided information on marital status (mean age, 68±13 years; 28% were women, and 63% were married). Sex and marital status modified the effect of RPM on all-cause death, with a significant 3-way interaction at 18 ( P =0.015) and 60 ( P =0.004) months. At 60 months, all-cause mortality ranged from 28% among married women receiving RPM to almost 60% among unmarried men receiving usual care. The greatest impact of RPM versus usual care on all-cause death was observed among married women: adjusted hazard ratios were 0.32 (95% CI, 0.10–0.98) and 0.44 (0.22–0.88) at 18 and 60 months, respectively. CONCLUSIONS: These findings indicate that the benefits from the RPM strategy HeartNetCare-HF in patients discharged after hospitalization for acute systolic HF were modulated by sex and marital status, both individually and in combination. Future studies are needed to evaluate whether tailoring RPM interventions according to patient sex and marital status optimizes outcomes in patients with HF.
- Open Access
Epigenetic signatures of biological vulnerability and residual risk in heart failure
Background: DNA methylation (DNAm) signatures capture cumulative lifestyle exposures and biological aging. This prospective study evaluated whether DNAm-based scores and epigenetic aging clocks are associated with clinical outcomes and mortality in a multinational cohort of patients with heart failure (HF). Methods: We studied 2,594 patients with HF from 40 countries in the Global Congestive Heart Failure (G-CHF) registry with whole-blood DNAm data. Fifteen published DNAm-based scores and epigenetic aging clocks reflecting lifestyle, environmental and physiological exposures, inflammation, frailty, mortality risk, and biological aging were derived. Associations with HF hospitalization, cardiovascular death, and all-cause death were assessed using multivariable Cox regression adjusted for age, sex, ancestry, the MAGGIC risk score, and NT-proBNP. Incremental prognostic value was compared to MAGGIC score and NT-proBNP. Extreme DNAm profiles were defined as scores or clocks exceeding ±1.5 standard deviations (s.d.) from the population mean. Results: Mean age was 62.7±14.0 years, 66.2% were male, and mean left ventricular ejection fraction was 40.1±14.1%. During a median follow-up of 3.0 years, 338 patients were hospitalized for HF, 349 died from cardiovascular causes, and 565 died from any cause. Higher epigenetic age and DNAm scores for CRP, frailty, and mortality were associated with increased risk, whereas higher diet-related DNAm scores were inversely associated. For all-cause death, adjusted hazard ratios per 1-s.d. were 1.36 (95% CI, 1.24-1.50) for GrimAge, 1.27 (95% CI, 1.17-1.38) for the DNAm score for CRP, 1.44 (95% CI, 1.28-1.63) for the DNAm score for frailty, and 1.48 (95% CI, 1.32-1.65) for the DNAm score for mortality, compared with 0.81 (95% CI, 0.75-0.88) and 0.86 (95% CI, 0.79-0.94) for the DNAm scores for Alternative Healthy Eating Index and Mediterranean Diet Score. These patterns were directionally consistent for cardiovascular death and weaker for HF hospitalization and were more pronounced among patients with lower clinical risk (MAGGICinteraction <0.05), particularly for all-cause death. Patients with 4-5 extreme-high DNAm scores or clocks had more than twice the risk of death (HR, 2.27; 95% CI, 1.65-3.13). Conclusions: DNAm-based scores and epigenetic aging clocks reflect multiple dimensions of biological vulnerability in HF and are associated with clinical outcomes and mortality beyond clinical risk factors. Clinical Perspective: What is new?: In 2,594 patients with heart failure (HF) from 40 countries, blood-based DNA methylation (DNAm) scores for inflammation, frailty, and mortality, as well as epigenetic aging measures, were associated with mortality and other clinical outcomes after adjustment for established risk factors and NT-proBNP. These associations were stronger among patients with lower clinical risk, suggesting that epigenetic signatures may capture biological vulnerability not fully reflected by conventional risk assessment. A greater accumulation of adverse epigenetic signatures was associated with progressively higher mortality risk; each additional extreme-high DNAm score or aging clock was associated with an 18% higher risk of death. What are the clinical implications?: DNA methylation may complement conventional clinical risk assessment by identifying biological vulnerability beyond established clinical risk factors. Multidimensional epigenetic profiling may provide a framework for molecular phenotyping of HF and for identifying patients with residual biological risk who may warrant further investigation.
Open AccessEpigenetic signatures of biological vulnerability and residual risk in heart failure
Background: DNA methylation (DNAm) signatures capture cumulative lifestyle exposures and biological aging. This prospective study evaluated whether DNAm-based scores and epigenetic aging clocks are associated with clinical outcomes and mortality in a multinational cohort of patients with heart failure (HF). Methods: We studied 2,594 patients with HF from 40 countries in the Global Congestive Heart Failure (G-CHF) registry with whole-blood DNAm data. Fifteen published DNAm-based scores and epigenetic aging clocks reflecting lifestyle, environmental and physiological exposures, inflammation, frailty, mortality risk, and biological aging were derived. Associations with HF hospitalization, cardiovascular death, and all-cause death were assessed using multivariable Cox regression adjusted for age, sex, ancestry, the MAGGIC risk score, and NT-proBNP. Incremental prognostic value was compared to MAGGIC score and NT-proBNP. Extreme DNAm profiles were defined as scores or clocks exceeding ±1.5 standard deviations (s.d.) from the population mean. Results: Mean age was 62.7±14.0 years, 66.2% were male, and mean left ventricular ejection fraction was 40.1±14.1%. During a median follow-up of 3.0 years, 338 patients were hospitalized for HF, 349 died from cardiovascular causes, and 565 died from any cause. Higher epigenetic age and DNAm scores for CRP, frailty, and mortality were associated with increased risk, whereas higher diet-related DNAm scores were inversely associated. For all-cause death, adjusted hazard ratios per 1-s.d. were 1.36 (95% CI, 1.24-1.50) for GrimAge, 1.27 (95% CI, 1.17-1.38) for the DNAm score for CRP, 1.44 (95% CI, 1.28-1.63) for the DNAm score for frailty, and 1.48 (95% CI, 1.32-1.65) for the DNAm score for mortality, compared with 0.81 (95% CI, 0.75-0.88) and 0.86 (95% CI, 0.79-0.94) for the DNAm scores for Alternative Healthy Eating Index and Mediterranean Diet Score. These patterns were directionally consistent for cardiovascular death and weaker for HF hospitalization and were more pronounced among patients with lower clinical risk (MAGGICinteraction <0.05), particularly for all-cause death. Patients with 4-5 extreme-high DNAm scores or clocks had more than twice the risk of death (HR, 2.27; 95% CI, 1.65-3.13). Conclusions: DNAm-based scores and epigenetic aging clocks reflect multiple dimensions of biological vulnerability in HF and are associated with clinical outcomes and mortality beyond clinical risk factors. Clinical Perspective: What is new?: In 2,594 patients with heart failure (HF) from 40 countries, blood-based DNA methylation (DNAm) scores for inflammation, frailty, and mortality, as well as epigenetic aging measures, were associated with mortality and other clinical outcomes after adjustment for established risk factors and NT-proBNP. These associations were stronger among patients with lower clinical risk, suggesting that epigenetic signatures may capture biological vulnerability not fully reflected by conventional risk assessment. A greater accumulation of adverse epigenetic signatures was associated with progressively higher mortality risk; each additional extreme-high DNAm score or aging clock was associated with an 18% higher risk of death. What are the clinical implications?: DNA methylation may complement conventional clinical risk assessment by identifying biological vulnerability beyond established clinical risk factors. Multidimensional epigenetic profiling may provide a framework for molecular phenotyping of HF and for identifying patients with residual biological risk who may warrant further investigation.
- Open Access
- 5 February 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (16) , 1507-1523
Anaemia predicts iron homoeostasis dysregulation and modulates the response to empagliflozin in heart failure with reduced ejection fraction: the EMPATROPISM-FE trial
Background and Aims: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) impact iron metabolism in patients with heart failure but mechanisms are incompletely understood. This post hoc analysis explored interrelations between iron homeostasis, cardiac structure/function, exercise capacity, haematopoiesis, and sympathetic activity at baseline, and the effects of 6-month treatment with empagliflozin vs. placebo by anaemia status in EMPATROPISM-FE study participants. Methods: Myocardial iron content (MIC, estimated by cardiac magnetic resonance T2* imaging), left ventricular (LV) volumes and LV ejection fraction (LVEF), exercise capacity, laboratory iron markers (LIM), haemoglobin/haematocrit, erythropoietin, and plasma norepinephrine were determined at baseline and 6 months. Results: At baseline, 24/80 participants (30%) had anaemia (haemoglobin < 13/ .10). Empagliflozin increased MIC (P < .012), improved exercise capacity, and activated haematopoiesis. Changes in LIM and norepinephrine suggested progressive systemic iron depletion and sympatholysis. LV reverse remodelling was greater in individuals with anaemia. Conclusions: Dysregulated cellular iron uptake/availability may be a shared mechanism in myocardial structural/functional impairment, reduced exercise capacity, and restricted haematopoiesis in heart failure, which are worse in patients with anaemia, and improve with empagliflozin. Empagliflozin increases MIC and decreases norepinephrine. Given this inverse association, sympatholysis may help explain the diverse cardiac and systemic benefits from SGLT2i therapy. Clinical Trial Registration: NCT03485222 (www.clinicaltrials.gov).
- 5 February 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (16) , 1507-1523
Open AccessAnaemia predicts iron homoeostasis dysregulation and modulates the response to empagliflozin in heart failure with reduced ejection fraction: the EMPATROPISM-FE trial
Background and Aims: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) impact iron metabolism in patients with heart failure but mechanisms are incompletely understood. This post hoc analysis explored interrelations between iron homeostasis, cardiac structure/function, exercise capacity, haematopoiesis, and sympathetic activity at baseline, and the effects of 6-month treatment with empagliflozin vs. placebo by anaemia status in EMPATROPISM-FE study participants. Methods: Myocardial iron content (MIC, estimated by cardiac magnetic resonance T2* imaging), left ventricular (LV) volumes and LV ejection fraction (LVEF), exercise capacity, laboratory iron markers (LIM), haemoglobin/haematocrit, erythropoietin, and plasma norepinephrine were determined at baseline and 6 months. Results: At baseline, 24/80 participants (30%) had anaemia (haemoglobin < 13/ .10). Empagliflozin increased MIC (P < .012), improved exercise capacity, and activated haematopoiesis. Changes in LIM and norepinephrine suggested progressive systemic iron depletion and sympatholysis. LV reverse remodelling was greater in individuals with anaemia. Conclusions: Dysregulated cellular iron uptake/availability may be a shared mechanism in myocardial structural/functional impairment, reduced exercise capacity, and restricted haematopoiesis in heart failure, which are worse in patients with anaemia, and improve with empagliflozin. Empagliflozin increases MIC and decreases norepinephrine. Given this inverse association, sympatholysis may help explain the diverse cardiac and systemic benefits from SGLT2i therapy. Clinical Trial Registration: NCT03485222 (www.clinicaltrials.gov).
- Open Access
- 4 December 2024
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 26, e63391
Telemonitoring for Chronic Heart Failure: Narrative Review of the 20-Year Journey From Concept to Standard Care in Germany
Background: Chronic heart failure (CHF) is a major cause of morbidity and mortality worldwide, placing a significant burden on health care systems. The concept of telemedicine for CHF was first introduced in the late 1990s, and since 2010, studies have demonstrated its potential to improve patient outcomes and reduce health care costs. Over the following decade, technological advancements and changes in health care policy led to the development of more sophisticated telemedicine solutions for CHF, including remote patient management through invasive or noninvasive telemonitoring devices, mobile apps, and virtual consultations. Years of public funding in Germany have generated evidence that remote patient management improves outcomes for patients with CHF, such as quality of life, and reduces hospital admissions. Based on these data, the Federal Joint Committee (Gemeinsamer Bundesausschuss; G-BA) decided, independently of the current European Society of Cardiology recommendations, to incorporate telemedicine as a standard digital intervention for high-risk patients with reduced left ventricular ejection fraction in Germany in 2020. Objective: This review aims to illustrate the journey from the initial concept through pioneering studies that led to telemedicine’s integration into standard care, and to share current experiences that have positioned Germany as a leader in cardiovascular telemedicine. Methods: We review and discuss existing literature and evidence on the development and implementation of telemonitoring for CHF in Germany over the past 20 years. Relevant studies, reports, and guidelines were identified through a comprehensive search of electronic databases, including PubMed, Google Scholar, and specialized journals focused on CHF telemonitoring. Results: Pioneering studies, such as the TIM-HF2 (Telemedical Interventional Management in Heart Failure II) and IN-TIME (Influence of Home Monitoring on Mortality and Morbidity in Heart Failure Patients with Impaired Left Ventricular Function) trials, demonstrated the effectiveness of remote patient management applications for patients with CHF in Germany and their applicability to current practices involving both invasive and noninvasive methods. Collaborations between researchers and technology developers overcame barriers, leading to sustainable improvements in patient care. Ongoing research on artificial intelligence applications for prioritizing and interpreting individual health data will continue to transform digital health care. Conclusions: The establishment of telemedical care for patients with HF across Europe is likely to benefit from experiences in Germany, where significant improvements have been achieved in the care of patients with HF.
- 4 December 2024
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 26, e63391
Open AccessTelemonitoring for Chronic Heart Failure: Narrative Review of the 20-Year Journey From Concept to Standard Care in Germany
Background: Chronic heart failure (CHF) is a major cause of morbidity and mortality worldwide, placing a significant burden on health care systems. The concept of telemedicine for CHF was first introduced in the late 1990s, and since 2010, studies have demonstrated its potential to improve patient outcomes and reduce health care costs. Over the following decade, technological advancements and changes in health care policy led to the development of more sophisticated telemedicine solutions for CHF, including remote patient management through invasive or noninvasive telemonitoring devices, mobile apps, and virtual consultations. Years of public funding in Germany have generated evidence that remote patient management improves outcomes for patients with CHF, such as quality of life, and reduces hospital admissions. Based on these data, the Federal Joint Committee (Gemeinsamer Bundesausschuss; G-BA) decided, independently of the current European Society of Cardiology recommendations, to incorporate telemedicine as a standard digital intervention for high-risk patients with reduced left ventricular ejection fraction in Germany in 2020. Objective: This review aims to illustrate the journey from the initial concept through pioneering studies that led to telemedicine’s integration into standard care, and to share current experiences that have positioned Germany as a leader in cardiovascular telemedicine. Methods: We review and discuss existing literature and evidence on the development and implementation of telemonitoring for CHF in Germany over the past 20 years. Relevant studies, reports, and guidelines were identified through a comprehensive search of electronic databases, including PubMed, Google Scholar, and specialized journals focused on CHF telemonitoring. Results: Pioneering studies, such as the TIM-HF2 (Telemedical Interventional Management in Heart Failure II) and IN-TIME (Influence of Home Monitoring on Mortality and Morbidity in Heart Failure Patients with Impaired Left Ventricular Function) trials, demonstrated the effectiveness of remote patient management applications for patients with CHF in Germany and their applicability to current practices involving both invasive and noninvasive methods. Collaborations between researchers and technology developers overcame barriers, leading to sustainable improvements in patient care. Ongoing research on artificial intelligence applications for prioritizing and interpreting individual health data will continue to transform digital health care. Conclusions: The establishment of telemedical care for patients with HF across Europe is likely to benefit from experiences in Germany, where significant improvements have been achieved in the care of patients with HF.
- Open Access
- 6 September 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (37) , 3669-3671
Remote heart failure management guided by pulmonary artery pressure home monitoring: rewriting the future?
Left: home monitoring of pulmonary artery pressure allows the detection of increases in cardiac filling pressure as the earliest sign of worsening heart failure and the treatment of ‘haemodynamic congestion’ at a time when patients are still asymptomatic, thus averting the need for in-hospital emergency treatment (top). Home monitoring of vital status and clinical signs and symptoms facilitates detection of ‘clinical congestion’ but, because changes occur late in the course of worsening heart failure, life-saving in-hospital emergency treatment can often not be averted (middle). Traditional standard care is based on clinical information collected at periodic outpatient visits that patients pay to their physicians. This may lead to delayed detection of worsening heart failure, frequent heart failure-related hospitalizations, and increased mortality in the intervals between visits (bottom). Right: key elements in the shaping of personalized remote management strategies for individuals with heart failure, which together facilitate a seamless care cycle to provide high-quality treatment at home and to enable improvements in mortality, morbidity, and quality of life. The traditional model of heart failure management with periodic outpatient consultations, using only information collected by technologies available to the healthcare provider at that time, should be replaced (or at least supplemented) by a more personalized patient-centric remote care approach. Adapted from Gheorghiade et al.,1 and modified according to Abraham et al.,2 Angermann et al.,3,4 and McBeath et al.5 AI, artificial intelligence; CIED, cardiac implantable electronic device; GRMT, guideline-recommended medical therapy; HF, heart failure; RPM, remote patient management; WHF, worsening heart failure.
- 6 September 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (37) , 3669-3671
Open AccessRemote heart failure management guided by pulmonary artery pressure home monitoring: rewriting the future?
Left: home monitoring of pulmonary artery pressure allows the detection of increases in cardiac filling pressure as the earliest sign of worsening heart failure and the treatment of ‘haemodynamic congestion’ at a time when patients are still asymptomatic, thus averting the need for in-hospital emergency treatment (top). Home monitoring of vital status and clinical signs and symptoms facilitates detection of ‘clinical congestion’ but, because changes occur late in the course of worsening heart failure, life-saving in-hospital emergency treatment can often not be averted (middle). Traditional standard care is based on clinical information collected at periodic outpatient visits that patients pay to their physicians. This may lead to delayed detection of worsening heart failure, frequent heart failure-related hospitalizations, and increased mortality in the intervals between visits (bottom). Right: key elements in the shaping of personalized remote management strategies for individuals with heart failure, which together facilitate a seamless care cycle to provide high-quality treatment at home and to enable improvements in mortality, morbidity, and quality of life. The traditional model of heart failure management with periodic outpatient consultations, using only information collected by technologies available to the healthcare provider at that time, should be replaced (or at least supplemented) by a more personalized patient-centric remote care approach. Adapted from Gheorghiade et al.,1 and modified according to Abraham et al.,2 Angermann et al.,3,4 and McBeath et al.5 AI, artificial intelligence; CIED, cardiac implantable electronic device; GRMT, guideline-recommended medical therapy; HF, heart failure; RPM, remote patient management; WHF, worsening heart failure.
- 1 April 2022
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 15 (4) , 368-378
Blood Pressure Drops During Hospitalization for Acute Heart Failure Treated With Serelaxin: A Patient-Level Analysis of 4 Randomized Controlled Trials
Background: Hypotensive events and drops in systolic blood pressure (SBP-drop) are frequent in patients hospitalized with acute heart failure. We investigated whether SBP-drops are associated with outcomes in patients treated with serelaxin. Methods: Patient-level retrospective analyses of 4 prospective trials investigating serelaxin in acute heart failure. Main inclusion criteria were SBP 125 to 180 mm Hg, pulmonary congestion, and elevated NT-proBNP (N-terminal pro-B-type natriuretic peptide). SBP-drops were prospectively defined as SBP100 mm Hg, a drop from baseline of 40 mm Hg from baseline. Outcomes were a short-term composite outcome (worsening heart failure, hospital readmission for heart failure or all-cause mortality through 14 days) and 180-day mortality. Results: Overall, 2559/11 226 (23%) patients had an SBP-drop. SBP-drop, versus no SBP-drop, was associated with a worse outcome: cumulative incidence of 180-day mortality (11% versus 9%, hazard ratio [HR]. 1.21 [95% CI, 1.05–1.39]; P =0.009) and the short-term outcome (11% versus 9%, HR, 1.29 [95% CI, 1.13–1.49]; P P =0.0005) and 1.22 (95% CI, 0.97–1.56; P =0.09), for each component respectively, with a P value for interaction of 0.05. SBP-drops were associated with a worse short-term outcome in the placebo group (HR, 1.46 [95% CI, 1.19–1.79]; P =0.0003), but not in the serelaxin-group (HR, 1.18 [95% CI, 0.97–1.42]; P =0.10); P interaction=0.003. Conclusions: SBP-drops in patients with acute heart failure and normal to high SBP at admission is associated with worse short- and long-term outcomes especially for SBP <100 mm Hg. However, in patients treated with the intravenous vasodilator serelaxin, SBP-drops seemed less harmful. Registration: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT02064868, NCT02007720, NCT01870778, NCT00520806.
- 1 April 2022
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 15 (4) , 368-378
Blood Pressure Drops During Hospitalization for Acute Heart Failure Treated With Serelaxin: A Patient-Level Analysis of 4 Randomized Controlled Trials
Background: Hypotensive events and drops in systolic blood pressure (SBP-drop) are frequent in patients hospitalized with acute heart failure. We investigated whether SBP-drops are associated with outcomes in patients treated with serelaxin. Methods: Patient-level retrospective analyses of 4 prospective trials investigating serelaxin in acute heart failure. Main inclusion criteria were SBP 125 to 180 mm Hg, pulmonary congestion, and elevated NT-proBNP (N-terminal pro-B-type natriuretic peptide). SBP-drops were prospectively defined as SBP100 mm Hg, a drop from baseline of 40 mm Hg from baseline. Outcomes were a short-term composite outcome (worsening heart failure, hospital readmission for heart failure or all-cause mortality through 14 days) and 180-day mortality. Results: Overall, 2559/11 226 (23%) patients had an SBP-drop. SBP-drop, versus no SBP-drop, was associated with a worse outcome: cumulative incidence of 180-day mortality (11% versus 9%, hazard ratio [HR]. 1.21 [95% CI, 1.05–1.39]; P =0.009) and the short-term outcome (11% versus 9%, HR, 1.29 [95% CI, 1.13–1.49]; P P =0.0005) and 1.22 (95% CI, 0.97–1.56; P =0.09), for each component respectively, with a P value for interaction of 0.05. SBP-drops were associated with a worse short-term outcome in the placebo group (HR, 1.46 [95% CI, 1.19–1.79]; P =0.0003), but not in the serelaxin-group (HR, 1.18 [95% CI, 0.97–1.42]; P =0.10); P interaction=0.003. Conclusions: SBP-drops in patients with acute heart failure and normal to high SBP at admission is associated with worse short- and long-term outcomes especially for SBP <100 mm Hg. However, in patients treated with the intravenous vasodilator serelaxin, SBP-drops seemed less harmful. Registration: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT02064868, NCT02007720, NCT01870778, NCT00520806.
- Open Access
- 16 December 2021
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 9 (1) , 786-790
Sex-Specific Bimodal Clustering of Left Ventricular Ejection Fraction in Patients with Acute Heart Failure
Aims There is an ongoing discussion whether the categorization of patients with heart failure according to left ventricular ejection fraction (LVEF) is scientifically justified and clinically relevant. Major efforts are directed towards the identification of appropriate cut-off values to correctly allocate heart failure-specific pharmacotherapy. Alternatively, an LVEF continuum without definite subgroups is discussed. This study aimed to evaluate the natural distribution of LVEF in patients presenting with acutely decompensated heart failure and to identify potential subgroups of LVEF in male and female patients. Methods and results We identified 470 patients (mean age 75 ± 11 years, n = 137 female) hospitalized for acute heart failure in whom LVEF could be quantified by Simpson's method in an in-hospital echocardiogram. Non-parametric modelling revealed a bimodal shape of the LVEF distribution. Parametric modelling identified two clusters suggesting two LVEF peaks with mean (variance) of 61% (9%) and 31% (10%), respectively. Sub-differentiation by sex revealed a sex-specific bimodal clustering of LVEF. The respective threshold differentiating between ‘high’ and ‘low’ LVEF was 45% in men and 52% in women. Conclusions In patients presenting with acute heart failure, LVEF clustered in two subgroups and exhibited profound sex-specific distributional differences. These findings might enrich the scientific process to identify distinct subgroups of heart failure patients, which might each benefit from respectively tailored (pharmaco)therapies.
- 16 December 2021
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 9 (1) , 786-790
Open AccessSex-Specific Bimodal Clustering of Left Ventricular Ejection Fraction in Patients with Acute Heart Failure
Aims There is an ongoing discussion whether the categorization of patients with heart failure according to left ventricular ejection fraction (LVEF) is scientifically justified and clinically relevant. Major efforts are directed towards the identification of appropriate cut-off values to correctly allocate heart failure-specific pharmacotherapy. Alternatively, an LVEF continuum without definite subgroups is discussed. This study aimed to evaluate the natural distribution of LVEF in patients presenting with acutely decompensated heart failure and to identify potential subgroups of LVEF in male and female patients. Methods and results We identified 470 patients (mean age 75 ± 11 years, n = 137 female) hospitalized for acute heart failure in whom LVEF could be quantified by Simpson's method in an in-hospital echocardiogram. Non-parametric modelling revealed a bimodal shape of the LVEF distribution. Parametric modelling identified two clusters suggesting two LVEF peaks with mean (variance) of 61% (9%) and 31% (10%), respectively. Sub-differentiation by sex revealed a sex-specific bimodal clustering of LVEF. The respective threshold differentiating between ‘high’ and ‘low’ LVEF was 45% in men and 52% in women. Conclusions In patients presenting with acute heart failure, LVEF clustered in two subgroups and exhibited profound sex-specific distributional differences. These findings might enrich the scientific process to identify distinct subgroups of heart failure patients, which might each benefit from respectively tailored (pharmaco)therapies.
- Open Access
- 25 August 2021
- Published by Springer Nature in Die Innere Medizin
- Vol. 62 (9) , 968-979
Mitteilungen der DGIM
- 25 August 2021
- Published by Springer Nature in Die Innere Medizin
- Vol. 62 (9) , 968-979
Open AccessMitteilungen der DGIM
- Open Access
- 2 February 2021
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 10 (3) , e017822
Trajectories of Left Ventricular Ejection Fraction After Acute Decompensation for Systolic Heart Failure: Concomitant Echocardiographic and Systemic Changes, Predictors, and Impact on Clinical Outcomes
Background: Prospective longitudinal follow‐up of left ventricular ejection fraction (LVEF) trajectories after acute cardiac decompensation of heart failure is lacking. We investigated changes in LVEF and covariates at 6‐months' follow‐up in patients with a predischarge LVEF ≤40%, and determined predictors and prognostic implications of LVEF changes through 18‐months' follow‐up. Methods and Results: Interdisciplinary Network Heart Failure program participants (n=633) were categorized into subgroups based on LVEF at 6‐months' follow‐up: normalized LVEF (>50%; heart failure with normalized ejection fraction, n=147); midrange LVEF (41%–50%; heart failure with midrange ejection fraction, n=195), or persistently reduced LVEF (≤40%; heart failure with persistently reduced LVEF , n=291). All received guideline‐directed medical therapies. At 6‐months' follow‐up, compared with patients with heart failure with persistently reduced LVEF, heart failure with normalized LVEF or heart failure with midrange LVEF subgroups showed greater reductions in LV end‐diastolic/end‐systolic diameters (both P P =0.002), more increased septal/posterior end‐diastolic wall‐thickness (both P P =0.002). Overall, LVEF increased further at 18‐months' follow‐up ( P P =0.048). However, LVEF worsened ( P =0.002) and LV end‐diastolic diameter increased ( P =0.047) in patients with heart failure with normalized LVEF hospitalized between 6‐months' follow‐up and 18‐months' follow‐up. Conclusions: Six‐month survivors of acute cardiac decompensation for systolic heart failure showed variable LVEF trajectories, with >50% showing improvements by ≥1 LVEF category. LVEF changes correlated with various parameters, suggesting multilevel reverse remodeling, were predictable from several baseline characteristics, and were associated with clinical outcomes at 18‐months' follow‐up. Repeat hospitalizations were associated with attenuation of reverse remodeling. Registration: URL: https://www.controlled‐trials.com ; Unique identifier: ISRCTN23325295.
- 2 February 2021
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 10 (3) , e017822
Open AccessTrajectories of Left Ventricular Ejection Fraction After Acute Decompensation for Systolic Heart Failure: Concomitant Echocardiographic and Systemic Changes, Predictors, and Impact on Clinical Outcomes
Background: Prospective longitudinal follow‐up of left ventricular ejection fraction (LVEF) trajectories after acute cardiac decompensation of heart failure is lacking. We investigated changes in LVEF and covariates at 6‐months' follow‐up in patients with a predischarge LVEF ≤40%, and determined predictors and prognostic implications of LVEF changes through 18‐months' follow‐up. Methods and Results: Interdisciplinary Network Heart Failure program participants (n=633) were categorized into subgroups based on LVEF at 6‐months' follow‐up: normalized LVEF (>50%; heart failure with normalized ejection fraction, n=147); midrange LVEF (41%–50%; heart failure with midrange ejection fraction, n=195), or persistently reduced LVEF (≤40%; heart failure with persistently reduced LVEF , n=291). All received guideline‐directed medical therapies. At 6‐months' follow‐up, compared with patients with heart failure with persistently reduced LVEF, heart failure with normalized LVEF or heart failure with midrange LVEF subgroups showed greater reductions in LV end‐diastolic/end‐systolic diameters (both P P =0.002), more increased septal/posterior end‐diastolic wall‐thickness (both P P =0.002). Overall, LVEF increased further at 18‐months' follow‐up ( P P =0.048). However, LVEF worsened ( P =0.002) and LV end‐diastolic diameter increased ( P =0.047) in patients with heart failure with normalized LVEF hospitalized between 6‐months' follow‐up and 18‐months' follow‐up. Conclusions: Six‐month survivors of acute cardiac decompensation for systolic heart failure showed variable LVEF trajectories, with >50% showing improvements by ≥1 LVEF category. LVEF changes correlated with various parameters, suggesting multilevel reverse remodeling, were predictable from several baseline characteristics, and were associated with clinical outcomes at 18‐months' follow‐up. Repeat hospitalizations were associated with attenuation of reverse remodeling. Registration: URL: https://www.controlled‐trials.com ; Unique identifier: ISRCTN23325295.